| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WT1 |
| Uniprot No | P19544 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-449aa |
| 氨基酸序列 | MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL |
| 预测分子量 | 51.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与WT1重组蛋白相关的文献示例(文献信息为模拟概括，实际引用需核实)：
---
1. **文献名称**: "WT1 recombinant protein vaccine induces immunologic and clinical responses in patients with myeloid malignancies"
**作者**: Rezvani K, et al.
**摘要**: 研究报道了一种基于WT1重组蛋白的疫苗联合佐剂在骨髓增生异常综合征和急性髓系白血病患者中的I期临床试验。结果显示疫苗可诱导WT1特异性CD4+和CD8+ T细胞免疫应答，部分患者出现疾病稳定或血液学指标改善。
---
2. **文献名称**: "In vitro induction of WT1-specific human CD8+ T cells using recombinant WT1 protein"
**作者**: Ohminami H, et al.
**摘要**: 通过重组WT1蛋白与树突状细胞共培养，成功在体外激活了WT1特异性细胞毒性T淋巴细胞(CTL)。这些CTL对表达WT1的肿瘤细胞系表现出特异性杀伤活性，为过继性T细胞疗法提供了实验依据。
---
3. **文献名称**: "Phase II trial of a WT1 recombinant protein vaccine in combination with montanide adjuvant for ovarian cancer"
**作者**: Keilholz U, et al.
**摘要**: 在复发性卵巢癌患者中评估WT1重组蛋白疫苗的疗效。研究显示，疫苗耐受性良好，约30%患者产生WT1特异性抗体，且部分患者出现肿瘤标志物(CA125)水平下降，提示潜在临床活性。
---
**注意**：以上文献标题和作者为示例性概括，具体研究需通过PubMed或Google Scholar以关键词“WT1 recombinant protein”、“WT1 vaccine”等检索真实文献。实际应用中建议引用经同行评议的高质量论文。
**Background of WT1 Recomcombinant Protein**
The Wilms' tumor 1 (WT1) gene, initially identified for its role in Wilms' tumor, a pediatric kidney cancer, encodes a zinc-finger transcription factor critical in embryonic development and organogenesis. WT1 regulates cell proliferation, differentiation, and apoptosis, exhibiting dual roles as both a tumor suppressor and oncogene depending on cellular context, splice variants, and post-translational modifications. Its overexpression is implicated in various malignancies, including leukemia, breast cancer, and glioblastoma, making it a promising therapeutic target.
Recombinant WT1 protein is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to generate purified WT1 antigens or functional domains for research and clinical applications. This protein retains epitopes or functional regions of native WT1. enabling studies on its molecular interactions, immune responses, and diagnostic/therapeutic development. Its recombinant form ensures consistency, scalability, and reduced batch-to-batch variability compared to native protein isolation.
In oncology, WT1 recombinant protein is pivotal in cancer immunotherapy. As a tumor-associated antigen, it serves as a base for WT1-targeted vaccines and T-cell therapies, with clinical trials showing efficacy in acute myeloid leukemia (AML) and solid tumors. It also aids in serological assays to detect anti-WT1 antibodies, correlating with disease progression. Beyond oncology, WT1 recombinant protein is used to study kidney and mesothelial tissue development, as well as WT1's role in transcriptional regulation.
Despite its potential, challenges remain, including WT1's variable expression across cancers and potential autoimmune reactions. Ongoing research focuses on optimizing recombinant protein formulations, adjuvants, and delivery systems to enhance therapeutic outcomes. The development of WT1 recombinant protein underscores its dual significance as a biological tool and a translational asset in precision medicine.
×
